NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Can-Fite BioPharma Ltd (TA: CANF)

 
CANF Technical Analysis
1
As on 10th Jul 2024 CANF STOCK Price closed @ 3.50 and we RECOMMEND N/A for LONG-TERM with Stoploss of 0.00 & N/A for SHORT-TERM with Stoploss of 0.00 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

CANFSTOCK Price

Open 3.50 Change Price %
High 3.60 1 Day N/A N/A
Low 3.40 1 Week 0.00 0.00
Close 3.50 1 Month 0.00 0.00
Volume 11057476 1 Year 0.00 0.00
52 Week High 0.00 | 52 Week Low 0.00
 
TA Israel Most Active Stocks
TA125 2008.05 1.06%
CANF 3.50 %
BEZQ 443.00 %
ORL 92.30 %
ELAL 447.70 %
LUMI 3242.00 %
POLI 3500.00 %
GNRS 54.20 %
TEVA 5929.00 %
FRSX 12.70 %
 
TA Israel Top Gainers Stocks
TDGN-L 171.50 17.55%
CNMD 45.10 10.54%
CNMD 45.10 10.54%
SFET 65.10 8.50%
SFET 65.10 8.50%
HUB 590.40 4.29%
HUB 590.40 4.29%
HUB 590.40 4.29%
HUB 590.40 4.29%
CHAM 349.00 3.90%
 
TA Israel Top Losers Stocks
KMNK 51.00 -23.19%
ULTR 74.10 -16.74%
MEAT 0.77 -9.41%
MEAT 0.77 -9.41%
DPRM 9.40 -5.05%
DRSL 1521.00 -3.55%
MITC 2.45 -3.54%
MITC 2.45 -3.54%
RTPT-L 28.20 -3.42%
GBUD 52.70 -2.23%
 
 
CANF
Daily Charts
CANF
Intraday Charts
Whats New @
Bazaartrend
CANF
Free Analysis
 
CANF Important Levels Intraday
SUPPORT0.00
SUPPORT0.00
SUPPORT0.00
SUPPORT0.00
SUPPORT0.00
SUPPORT0.00
SUPPORT0.00
SUPPORT0.00
 
CANF Forecast July 2024
4th UP Forecast0
3rd UP Forecast0
2nd UP Forecast0
1st UP Forecast0
1st DOWN Forecast0
2nd DOWN Forecast0
3rd DOWN Forecast0
4th DOWN Forecast0
 
CANF Weekly Forecast
4th UP Forecast0.00
3rd UP Forecast0.00
2nd UP Forecast0.00
1st UP Forecast0.00
1st DOWN Forecast0.00
2nd DOWN Forecast0.00
3rd DOWN Forecast0.00
4th DOWN Forecast0.00
 
CANF Forecast2024
4th UP Forecast0
3rd UP Forecast0
2nd UP Forecast0
1st UP Forecast0
1st DOWN Forecast0
2nd DOWN Forecast0
3rd DOWN Forecast0
4th DOWN Forecast0
 
 
CANF Other Details
Segment EQ
Market Capital 9450308608.00
Sector Healthcare
Industry Biotechnology
Offical website >
 
CANF Address
CANF
 
CANF Latest News
 
Your Comments and Response on Can-Fite BioPharma Ltd
 
CANF Business Profile
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver and inflammatory disease, COVID-19 and erectile dysfunction. The company's lead drug candidate CF101 (Piclidenoson), which is in Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops CF102 (Namodenoson) that is completed Phase II clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase II trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah-Tikva, Israel. Address: 10 Bareket Street, Petah Tikva, Israel, 4951778
 
2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service